Alinidine

Alinidine

Systematic (IUPAC) name
N-(2,6-dichlorophenyl)-N-(prop-2-en-1-yl)-4,5-dihydro-1H-imidazol-2-amine
Clinical data
Legal status	Uncontrolled
Identifiers
CAS Number	33178-86-8
ATC code	none
PubChem	CID 36354
ChemSpider	33429
UNII	E7IDJ8DS1D
ChEMBL	CHEMBL278581
Chemical data
Formula	C12H13Cl2N3
Molar mass	270.16 g/mol
SMILES Clc2cccc(Cl)c2N(/C1=N/CCN1)C\C=C
InChI InChI=1S/C12H13Cl2N3/c1-2-8-17(12-15-6-7-16-12)11-9(13)4-3-5-10(11)14/h2-5H,1,6-8H2,(H,15,16) Key:OXTYVEUAQHPPMV-UHFFFAOYSA-N
(what is this?)  (verify)

Alinidine (ST567) is a negative chronotrope that was developed in the 1970s and 1980s. It causes bradycardia by inhibiting the pacemaker current by altering the maximal channel conductance and alter the voltage threshold.^[1] The development of alinidine was halted because it was not sufficiently specific for its target. It also has a blocking effect on calcium channels and potassium channels. It also causes elongation of re-polarisation after an action potential.^[2]

Alinidine did not improve outcomes among patients with acute myocardial infarction in a randomized controlled trial.^[3]

References

1. Snyders DJ, Van Bogaert P-P: Alinidine modifies the pacemaker current in sheep Purkinje fibers. Pflugers Arch 1987, 410:83-91
2. Current Opinion in Pharmacology 2007, 7:208–213
3. Van de Werf F, Janssens L, Brzostek T, Mortelmans L, Wackers FJ, Willems GM; et al. (1993). "Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy.". J Am Coll Cardiol 22 (2): 407–16. doi:10.1016/0735-1097(93)90044-2. PMID 8335810.